E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The effect of AZARGA(R) on the central and spacial-temporal contrast sensitivity of patients with normal tension glaucoma will be examined. Healthy controls are required to prove the disease specific effect of the trial drug. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019279 |
E.1.2 | Term | Heart failure |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003555 |
E.1.2 | Term | Asthma bronchial |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10021005 |
E.1.2 | Term | Hypoglycemia |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000456 |
E.1.2 | Term | Acid base balance |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054844 |
E.1.2 | Term | Anaphylactic reaction to drug |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to examine if lowering of the intraocular pressure by combined local application of timolol/ brinzolamide improves the spacial-temporal contrast sensitivity of patients with normal tension glaucoma. |
|
E.2.2 | Secondary objectives of the trial |
By testing the retinal sensitivity to distinguish light stimuli and the subjective contrast sensitivity with and without photostress, it is possible to determine, whether in glaucoma predominantly the magno-cellular or the parvo-cellular sytem of the retinal ganglion cells is sensitive to the treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
OVERALL ● Patients from the clinic and outpatient clinic of Ophthalmology, Erlangen ● Age 18 to 75 years ● Both sexes (10 ± 1 male or female subjects, respectively, each per group) ● Ability to sign an informed consent
GROUP OF GLAUCOMA ● 20 patients with normal tension glaucoma (untreated intraocular pressur <21 mmHg) and no systemic neurological diseases ● At least one eye with stage 1 -4 according to Jonas scale ● Glaucoma specific surgery is allowed ● Visual field defect > 2 dB and/or ● Spatial-temporal contrast sensitivity ≥ 5 (Score according to Patel) and/or ● Reduced peripapillary mean retinal nerve fiber layer thickness (Heidelberg Retinatomography, < 0.180 mm)
CONTROL GROUP ● 20 patients without systemic neurological disease and without eye diseases, which comprise the visual pathway (e.g. eye lid tumor, pterygium, stenosis of te lacrimal duct) ● intraocular pressur <21 mmHg ● normal morphology of the papilla (stage 0 according to Jonas) ● Visual field defect ≤ 2dB and ● Score of the spatial-temporal contrast sensitivity < 5 and ● Peripapillary mean retinal nerve fiber layer thickness ≥ 0.180 mm) |
|
E.4 | Principal exclusion criteria |
● Glaucoma of other origin (e.g. angle closure glaucoma, pseudoexfoliative glaucoma, pigmentary glaucoma) ● Other eye diseases involving the retina and visual pathway ● Functional monophthalmia ● Preexisting damage of the cornea ● Use of contact lenses ● Ametropia > ±4,0 dpt sph and > ±2,0 dpt cyl ● History of heart failure, cardiogenic shock, , Prinzmetal angina, arterial hypotension, sinus bradycardia, av block II° and III° ● Asthma bronchiale, severe COPD, bronchial hyperreactivity ● Severe hepatic or renal impairment (creatinine clearance <30 ml/min) ● Diabetes mellitus, affinity to spontanous hypoglycemia ● Severe anaphylactic reaction in history ● Hyperchloremic acidosis, hyperthyreosis ● Hypersensitivity to beta-adrenergic blocking agents or sulfonamides ● Pregnancy, lactation period ● Application of oral calcium channel blocker, guanethidine, antarrhythmic agents, digitalis glycosides, parasympathicomimetics, clonidine, CYP2D6 inhibitors [quinidine, cimetidine], antidiabetics, beta-adrenergic blockers or inhibitors of carbonic anhydrase ● Participation in another clinical trial within the last 4 weeks |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The Freiburger Vision Test "FrACT" will be implemented for examination. The therapy will be considered effective, if in the glaucoma group the time of readaption after photo stress and the threshold of contrast sensitivity changes significantly (p ≤ 0,05) after treatment.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined by the limited application of the trial drug (8 weeks). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |